Press Releases
September 16, 2024
Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
September 09, 2024
Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients
September 05, 2024
Geographic Atrophy treatment to move to Phase II
Newsbits
July 30, 2024
Boehringer Ingelheim invests in precision cancer treatments
July 17, 2024
Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
June 03, 2024
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Current Events
Past Events
Event